Agrylin Adds Contraindication For Patients With Severe Hepatic Impairment
This article was originally published in The Pink Sheet Daily
Executive Summary
Shire's "Dear Doctor" letter describes revised Agrylin labeling, which includes a contraindication for patients with severe hepatic impairment and a warning that reduced dosage should be used in patients with moderate hepatic impairment.